European Medicines Agency recommends suspension of marketing authorisations for sibutramine (EMA Press release, 21 January 2010)

BioSciAlliance - create your profile today and be part of the endocrine community! (1)

Top obesity drug sibutramine being suspended (BBC News Online, 22 January 2010)

22 Jan 2010

Following recommendations from the European Medicines Agency, the MHRA is suspending the use of the anti-obesity drug sibutramine in the UK after new evidence linked the drug with an increased risk of non-fatal heart attacks and strokes.

Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story

Top stories

Call for nominations for Awards Committee Chair
30 Oct 2024

James M Tanner Award - 2025 nominations open
30 Oct 2024

Would you like to host the BSPED annual meeting?
21 Oct 2024

Most read